Ionis Pharmaceuticals, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
Ionis Pharmaceuticals is an RNA-targeted therapeutics company operating as a single segment. The filing covers the unaudited three months ended March 31, 2022, with comparative results for the three months ended March 31, 2021. The company marketed SPINRAZA, TEGSEDI and WAYLIVRA and had six medicines in Phase 3 development for eight indications.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $141.9 million | $111.6 million | Up 27% |
| Commercial revenue | $72.3 million | $84.4 million | Down 14% |
| Research and development revenue | $69.6 million | $27.2 million | Up 156% |
| Operating expenses | $199.4 million | $203.6 million | Down 2% |
| Loss from operations | $(57.5) million | $(92.0) million | Improved $34.5 million |
| Net loss | $(65.2) million | $(89.9) million | Improved $24.7 million |
| Net loss per share | $(0.46) | $(0.64) | Improved |
| Net cash used in operations | $(31.7) million | $(54.7) million | Improved $23.0 million |
- Approximate operating margin was negative 40.5%, compared with negative 82.4% in Q1 2021; approximate net margin was negative 45.9%, compared with negative 80.5%.
- Revenue included $20 million of AstraZeneca cost-sharing revenue for eplontersen development and approximately $40 million of Biogen payments related to advancing partnered neurology programs. Biogen also contributed $18 million of milestone payments recognized in full and a $10 million ION859 milestone.
- SPINRAZA royalties declined to $53.8 million from $60.0 million. Biogen reported $473 million of worldwide SPINRAZA sales in Q1 2022.
- TEGSEDI and WAYLIVRA revenue declined to $6.2 million from $19.8 million following the transition of distribution activities to Sobi, with Ionis receiving distribution fees rather than recognizing prior product-sale revenue.
- R&D expense rose to $161.1 million from $139.8 million, driven by the expanded late-stage pipeline. SG&A declined to $34.1 million from $61.2 million, reflecting Akcea integration and commercial restructuring savings.
- Cash and cash equivalents were $542.5 million and short-term investments were $1.510 billion at March 31, 2022, totaling approximately $2.1 billion. The company reported $31.7 million of operating cash burn for the quarter.
- Available-for-sale and equity securities had fair value of approximately $1.600 billion. Unrealized losses on debt securities were $15.8 million, and the company recognized a $6.6 million loss on investments, primarily reflecting equity investment declines.
- Long-term obligations included approximately $632.5 million principal of 0% convertible notes due April 2026, $548.8 million principal of 0.125% convertible notes due December 2024, and mortgage debt with a carrying value of $59.5 million.
- Total contractual obligations were approximately $1.284 billion, including convertible debt, mortgages, operating leases and other obligations.
Material changes versus the prior comparable period
- Total revenue increased primarily because of partner-funded development activities and milestone payments, while commercial revenue decreased because of the Sobi distribution model and lower SPINRAZA royalties.
- Operating expenses excluding non-cash equity compensation increased to $173.1 million from $165.7 million. Non-cash stock-based compensation declined to $26.3 million from $37.9 million.
- Development spending increased substantially for eplontersen, olezarsen and other late-stage programs. Eplontersen development expense was $27.0 million, compared with $13.3 million in Q1 2021.
- Net cash used in investing activities was $287.5 million, compared with $78.9 million of investing cash inflow in Q1 2021, primarily reflecting purchases of short-term investments.
- Accumulated deficit increased to $1.225 billion from $1.160 billion at December 31, 2021, while stockholders’ equity declined to $709.6 million from $771.7 million, including the effect of net loss and unrealized investment losses.
Guidance, outlook, commentary, risks and unusual items
- Management expects operating expenses excluding non-cash equity compensation to continue increasing during the remainder of 2022 as Ionis advances its pipeline, expands technology and prepares for commercialization.
- AstraZeneca funds 55% of global Phase 3 eplontersen development costs. Ionis reported $36 million of first-quarter eplontersen development expense and $20 million of related cost-sharing revenue. Medical affairs and commercialization costs were reported net of AstraZeneca funding.
- Management expected eplontersen NEURO-TTRansform data in mid-2022 and CARDIO-TTRansform data in the first half of 2025 after increasing the latter study’s size and duration. These are forward-looking expectations and remain subject to clinical and regulatory risk.
- FDA granted orphan drug designation to eplontersen. Enrollment was ongoing for Phase 3 programs involving olezarsen, donidalorsen and ION363; enrollment was ongoing in the partner-led pelacarsen program. Biogen continued evaluating a regulatory path for tofersen after the Phase 3 VALOR study did not meet its primary endpoint.
- Ionis discontinued IONIS-C9 Rx after lack of demonstrated patient benefit in a Phase 1/2 study.
- COVID-19 continued to pose risks to commercial access, supply chains, clinical enrollment and study timelines. The filing also identifies risks from the Russia-Ukraine war, inflation, cybersecurity, manufacturing capacity, reimbursement, competition and reliance on partners.
- The company disclosed two stockholder-related legal proceedings involving the Akcea take-private transaction and director compensation. Ionis stated that the claims were without merit or that defendants intended to seek dismissal; the filing did not provide a clear estimated financial exposure.
- Beginning in 2022, required capitalization and amortization of U.S. research and development expenditures under the Tax Cuts and Jobs Act resulted in $1.1 million of income tax expense, compared with $0.1 million in Q1 2021.
- Management stated that disclosure controls and procedures were effective as of March 31, 2022 and that there were no material changes in internal control over financial reporting during the quarter.
Important facts investors should verify
- Whether SPINRAZA royalties stabilize or continue to decline amid competition, pricing pressure and changes in patient starts.
- The sustainability and timing of milestone and collaboration revenue, particularly Biogen payments and AstraZeneca eplontersen cost sharing.
- Progress, enrollment, safety results and regulatory milestones for eplontersen, olezarsen, donidalorsen, ION363, pelacarsen and tofersen.
- Whether increasing R&D and commercialization spending can be supported by operating cash flow and collaboration revenue.
- The liquidity impact of operating losses, the 2024 and 2026 convertible-note maturities, and potential dilution from conversion features and warrants.
- The commercial performance of TEGSEDI and WAYLIVRA under Sobi and PTC distribution arrangements.
- Potential effects of COVID-19, the Russia-Ukraine war, supply-chain constraints, inflation, reimbursement changes and competitive products on clinical and commercial execution.